President Donald Trump’s Most Favored Nation (MFN) pricing policy for prescription medicines could be behind a growing trend among drugmakers to delay launches and withdraw their products in Europe, ...

The Trump Administration has announced its desire to impose price controls on drugs – officially called a most favored nation (MFN) policy. Essentially, the policy sets the price for the targeted ...

Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry experts. The US bears the highest drug costs globally ...

The MFN executive order aims to reduce US drug prices by aligning them with international prices, facing legal and industry challenges. Pharmacy benefit managers (PBMs) significantly influence US drug ...

Consumer advocacy organization Public Citizen has filed (PDF) a Freedom of Information Act (FOIA) lawsuit against the Department of Health and Human Services (HHS) and the Department of Commerce (DOC) ...

In a new survey of health policy experts conducted by the Cornell Health Policy Center, respondents expressed uncertainty about the effects of a most favored nation (MFN) prescription drug pricing ...

The Trump administration reignited the U.S. drug pricing debate by signing a sweeping Executive Order on May 12, introducing a “Most Favored Nation” (MFN) pricing framework. This policy seeks to ...

On July 31, the Trump administration called on drug manufacturers to lower prescription drug prices in the U.S. to "most favored nation" – or MFN – pricing, the lowest cost paid for the same ...

President Donald Trump has found himself in an odd juxtaposition as traditional allies are pushing back on his Most Favored Nation (MFN) plan to reduce the price of prescription drugs. In a letter to ...

In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America (MBAA) ...